View Financial HealthRevvity 배당 및 자사주 매입배당 기준 점검 0/6Revvity 은(는) 현재 수익률이 0.24% 인 배당금 지급 회사입니다. 다음 지급일은 13th November, 2026 이며 배당락일은 다음과 같습니다. 23rd October, 2026.핵심 정보0.2%배당 수익률3.6%자사주 매입 수익률총 주주 수익률3.8%미래 배당 수익률0.2%배당 성장률0%다음 배당 지급일13 Nov 26배당락일23 Oct 26주당 배당금n/a배당 성향13%최근 배당 및 자사주 매입 업데이트Declared Dividend • Aug 10Second quarter dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 23rd October 2026 Payment date: 13th November 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 7%. Cash payout ratio: 6%.공고 • Aug 02Revvity Board Declares Quarterly Dividend, Payable on November 13, 2026The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026.모든 업데이트 보기Recent updates공고 • Aug 11Revvity Launches Superflex Prenatal Screening SystemRevvity, Inc. announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows. The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes and hypertension. Despite international guidelines recommending screening, access has historically been limited to high-throughput centralized laboratories. SuperFlex addresses these gaps by delivering three core advantages: Accessible entry — affordable instrument cost with just one annual maintenance, and no reagent wastage even when sample volumes are low; Operational simplicity — a user-friendly design that minimizes training requirements, to be seamlessly integrated with Revvity’s LifeCycle software for streamlined risk assessment and LIMS data transfer; Flexible throughput — continuous sample loading delivers results in as little as 14 minutes per test, accommodating both urgent and routine workflows. The platform also includes a test menu for both first- and second-trimester biochemical prenatal screening, enabling a versatile, cost-effective, random-access solution well-suited for decentralized testing. The SuperFlex platform will initially be available in all markets that accept CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.Declared Dividend • Aug 10Second quarter dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 23rd October 2026 Payment date: 13th November 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 7%. Cash payout ratio: 6%.공고 • Aug 04Revvity, Inc. Provides Earnings Guidance for the Full Year 2026Revvity, Inc. provided earnings guidance for the full year 2026. For the period, the company on a pro forma basis, the Company forecasts total revenue of $2.83 billion -$2.86 billion.공고 • Aug 02Revvity Board Declares Quarterly Dividend, Payable on November 13, 2026The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026.공고 • Jul 08Revvity, Inc. to Report Q2, 2026 Results on Aug 04, 2026Revvity, Inc. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on Aug 04, 2026공고 • Jun 25Revvity Launches Signals AI, A Native Agentic Framework For Accelerating Scientific R&DRevvity, Inc. announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows. Signals AI introduces a new intelligence layer into the Signals One platform, allowing scientists to engage directly with connected R&D knowledge and dynamically recast it for any purpose. Signals AI helps researchers transform existing knowledge into the form needed to drive decisions and execution. Grounded in structured scientific data, domain ontologies and validated scientific algorithms, Signals AI delivers traceable, scientifically relevant responses through natural language and interactive views of molecules, sequences, experimental results and connected knowledge. This helps scientists understand, validate and act in context while maintaining scientific rigor. This integrated intelligence transforms scientific software from a system of record into a system of scientific understanding, helping researchers move from data to insight, and from insight to action, faster than ever before. Select capabilities of Signals AI are available, with additional capabilities expected to be released and enhanced in the coming weeks.예정된 배당 지급오늘Aug 18 2026배당락일Oct 23 2026배당 지급일Nov 13 202621 days (배당락일 기준)다음 배당금을 받으려면 앞으로 65 days일 이내에 매수하세요지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: PKN German 시장에서 주목할만한 배당금을 지급하지 않으므로 지급이 안정적인지 확인할 필요가 없습니다.배당금 증가: PKN German 시장에서 주목할만한 배당금을 지급하지 않으므로 지급액이 증가하는지 확인할 필요가 없습니다.배당 수익률 vs 시장Revvity 배당 수익률 vs 시장PKN의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PKN)0.2%시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.7%업계 평균 (Life Sciences)0.8%분석가 예측 (PKN) (최대 3년)0.2%주목할만한 배당금: PKN 의 배당금( 0.24% )은 German 시장에서 배당금 지급자의 하위 25%( 1.47% )와 비교해 주목할 만하지 않습니다.고배당: PKN 의 배당금( 0.24% )은 German 시장에서 배당금 지급자의 상위 25%( 4.68% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: PKN German 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: PKN German 시장에서 주목할만한 배당금을 지급하지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/17 14:31종가2026/08/17 00:00수익2026/07/05연간 수익2025/12/28데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Revvity, Inc.는 38명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Catherine Ramsey SchulteBairdRobert BambergerBairdLuke SergottBarclays35명의 분석가 더 보기
Declared Dividend • Aug 10Second quarter dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 23rd October 2026 Payment date: 13th November 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 7%. Cash payout ratio: 6%.
공고 • Aug 02Revvity Board Declares Quarterly Dividend, Payable on November 13, 2026The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026.
공고 • Aug 11Revvity Launches Superflex Prenatal Screening SystemRevvity, Inc. announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows. The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes and hypertension. Despite international guidelines recommending screening, access has historically been limited to high-throughput centralized laboratories. SuperFlex addresses these gaps by delivering three core advantages: Accessible entry — affordable instrument cost with just one annual maintenance, and no reagent wastage even when sample volumes are low; Operational simplicity — a user-friendly design that minimizes training requirements, to be seamlessly integrated with Revvity’s LifeCycle software for streamlined risk assessment and LIMS data transfer; Flexible throughput — continuous sample loading delivers results in as little as 14 minutes per test, accommodating both urgent and routine workflows. The platform also includes a test menu for both first- and second-trimester biochemical prenatal screening, enabling a versatile, cost-effective, random-access solution well-suited for decentralized testing. The SuperFlex platform will initially be available in all markets that accept CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.
Declared Dividend • Aug 10Second quarter dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 23rd October 2026 Payment date: 13th November 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 7%. Cash payout ratio: 6%.
공고 • Aug 04Revvity, Inc. Provides Earnings Guidance for the Full Year 2026Revvity, Inc. provided earnings guidance for the full year 2026. For the period, the company on a pro forma basis, the Company forecasts total revenue of $2.83 billion -$2.86 billion.
공고 • Aug 02Revvity Board Declares Quarterly Dividend, Payable on November 13, 2026The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026.
공고 • Jul 08Revvity, Inc. to Report Q2, 2026 Results on Aug 04, 2026Revvity, Inc. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on Aug 04, 2026
공고 • Jun 25Revvity Launches Signals AI, A Native Agentic Framework For Accelerating Scientific R&DRevvity, Inc. announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows. Signals AI introduces a new intelligence layer into the Signals One platform, allowing scientists to engage directly with connected R&D knowledge and dynamically recast it for any purpose. Signals AI helps researchers transform existing knowledge into the form needed to drive decisions and execution. Grounded in structured scientific data, domain ontologies and validated scientific algorithms, Signals AI delivers traceable, scientifically relevant responses through natural language and interactive views of molecules, sequences, experimental results and connected knowledge. This helps scientists understand, validate and act in context while maintaining scientific rigor. This integrated intelligence transforms scientific software from a system of record into a system of scientific understanding, helping researchers move from data to insight, and from insight to action, faster than ever before. Select capabilities of Signals AI are available, with additional capabilities expected to be released and enhanced in the coming weeks.